Elismetrep
Phase 3
Elismetrep is one of 37 therapeutic programs targeting Migraine. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
36
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
105 competitors in Migraine
#DrugCompanyPhaseTrials
1Zonegran
AAzurity Pharmaceuticals
Phase 3
Magnesium
SSpherium Biomed
Phase 3
Elismetrep
KKallyope Inc.
Phase 3
Flunarizine
AAspartes Pharmaceuticals, Inc.
Phase 3
BAT7104
TevaPhase 3
Tizanidine Hydrochloride
EElan Pharmaceuticals
Phase 3
Bayer Aspirin
BayerPreclinical
Cymbalta
Jazz PharmaceuticalsPreclinical
Adempas
BayerPreclinical
Cervidil
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine3 trials
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Elismetrep. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]
- Company
- KKallyope Inc.